InSightec's Non-Invasive MR Guided Focused Ultrasound (MRgFUS) Technology to be Featured at NESA 2006 New European Surgical Conference

Physicians to Discuss Role of ExAblate(r) 2000 for Treating Uterine

Fibroids, Benign and Cancerous Tumors

Jan 19, 2006, 00:00 ET from InSightec Ltd.

    HAIFA, Israel, January 19 /PRNewswire/ -- InSightec Ltd. announced today
 that its non-invasive MR guided focused ultrasound (MRgFUS) technology, will
 be featured in four presentations at the New European Surgical Academy's NESA
 Days 2006, an interdisciplinary endoscopy conference focused on optimizing,
 simplifying and standardizing surgical procedures. The meeting takes place
 January 19 to 21, 2006 at the Hilton Hotel in Berlin, Germany and the
 presentations will highlight the global use of MRgFUS as a new, non-invasive
 surgical treatment for a variety of benign and cancerous tumors.
     MRgFUS combines Magnetic Resonance Imaging (MRI) to visualize tissue in
 the body, plan and monitor the treatment and outcome in real time and high
 intensity focused ultrasound energy to thermally ablate (destroy) tissue. MR
 thermal feedback, provided uniquely by the system, allows the physician to
 control and adjust the treatment to ensure that the targeted tumor is fully
 treated and other tissue is avoided.
     ExAblate 2000 is the only MRgFUS system approved by the FDA (U.S. Food
 and Drug Administration) as a non-invasive, outpatient procedure to treat
 uterine fibroids. The device also has the European CE mark and ISO 9001.Over
 1500 women have been treated worldwide for symptomatic uterine fibroids.
     The company has begun clinical trials to study the technology's use in
 other indications including breast, bone, liver and brain tumors. Currently,
 clinical trials are being conducted for metastatic bone and liver tumors at
 Charite Hospital in Berlin and St. Mary's Hospital in London.
     Following are ExAblate talks at NESA Days 2006:
     Presentation Title              Presenter
     The Use of FUS on Malignancies  Moshe Zvi Papa, MD
     Focused Ultrasound Therapy:     Elizabeth A. Stewart, MD
     Uterine Fibroids and Beyond
     Preliminary Experience with     Alexander Beck, MD
     Treatment of Bone and Liver
     tumors with MR guided Focused
     Round Table: From Surgery to    Zion Ben Rafael, MD, Moshe Zvi
     Minimal Invasive and            Papa , MD, Gralf Popken, MD,
     Non-invasive Procedures         Elizabeth A. Stewart, MD,
                                     Gerhard Buess, MD, Michael
                                     Stark, MD, Dov Maor, PhD.
     About Uterine Fibroids
     Uterine fibroids are benign growths in the uterus that affect
 approximately 13 million women of child bearing age in the U.S. Each year
 approximately 200,000 women have hysterectomies to treat uterine fibroids.
 Unlike hysterectomy, myomectomy and UAE, this technology is completely
 non-invasive using MRgFUS to thermally ablate (destroy) tumors in the uterus.
 For women this means no hospital stay and only 2-3 days of recovery as
 opposed to the one week (UAE); two weeks (myomectomy); or six weeks
 (hysterectomy) usually associated with treatment of this condition.
     ExAblate has been recognized for its innovation and potential to serve
 mankind and has been awarded the 2004 EU's Information Society Technologies
 grand prize, the The Wall Street Journal's 2004 Technology Innovation Awards,
 and Advanced Imaging's 2005 Solutions of the Year.
     About InSightec
     InSightec Ltd. is a privately held company owned by Elbit Medical Imaging
 (EMI), General Electric, private investors and employees. It was founded in
 1999 to develop the breakthrough MR guided Focused Ultrasound technology and
 transform it into the next generation operating room. Headquartered near
 Haifa, Israel, the company has over 120 employees and has invested more than
 $100 million in research, development, and clinical investigations. Its U.S.
 headquarters are located in Dallas, Texas. For more information, please go
     About NESA
     NESA was founded in 2004, and includes members, departments, and
 hospitals in 27 countries. NESA deals among others with re-evaluation of
 surgical procedures in order to optimize, simplify and standardize them.
 NESA's five disciplines are: general surgery, obstetrics and gynecology,
 urology, otolaryngology, and anaesthesiology. In NESA DAYS 2006 experts with
 high international reputation will present a wide variety of re-evaluated and
 optimized surgical endoscopic procedures next to new developments in basic
     Contact Information:
     InSightec Ltd.
     Tel: +972-4-813-1313
     For media inquiries, contact:
     Fern Lazar
     Lazar Partners, Ltd.
     Tel: +1-(212)-867-1762
     For more information about uterine fibroids, please visit

SOURCE InSightec Ltd.